C. Desjardins

Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

Y. Wong, E. Schuck, Jan-Shiang Taur, 2011, Xenobiotica; the fate of foreign compounds in biological systems.

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

C. Takimoto, S. Mani, M. Mita, 2009, Clinical Cancer Research.

Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity.

Yanke Yu, B. Slusher, B. Littlefield, 2016, Cancer research.

Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice.

Y. Wong, E. Schuck, Yanke Yu, 2013, International journal of pharmaceutics.

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma.

Y. Wong, Xiaofang Li, C. Desjardins, 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery.

Y. Liu, G. Cavaletti, S. Feinstein, 2018, Cancer research.

Eribulin shows high concentration and long retention in xenograft tumor tissues

E. Schuck, W. G. Lai, C. Desjardins, 2017, Cancer Chemotherapy and Pharmacology.

Interactions between the chemotherapeutic agent eribulin mesylate (E7389) and P-glycoprotein in CF-1 abcb1a-deficient mice and Caco-2 cells

E. Schuck, Jan-Shiang Taur, C. Desjardins, 2011, Xenobiotica; the fate of foreign compounds in biological systems.